<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04479241</url>
  </required_header>
  <id_info>
    <org_study_id>LUMINOS-101</org_study_id>
    <nct_id>NCT04479241</nct_id>
  </id_info>
  <brief_title>LUMINOS-101: PVSRIPO and Pembrolizumab in Patients With Recurrent Glioblastoma</brief_title>
  <official_title>A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of PVSRIPO and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istari Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istari Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 single arm trial in patients with rGBM will characterize the efficacy, safety,&#xD;
      tolerability and initial efficacy of PVSRIPO intratumoral infusion followed by intravenous&#xD;
      pembrolizumab 14 to 28 days later, and every 3 weeks, thereafter.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 21, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR), Duration of response (DOR) and Durable Radiographic Response (DRR)</measure>
    <time_frame>24 months</time_frame>
    <description>Objective response rate (comprised of patients meeting an objective radiographic response or ORR): Patients achieving a CR or PR.&#xD;
DOR: Time from first ORR observed (once confirmed) until PD first observed (once confirmed) or death; whichever comes first.&#xD;
DRR: An ORR that persists for ≥ 6 months.&#xD;
All response must be confirmed via two consecutive MRI assessments at least 4 weeks apart. If on bevacizumab therapy when response first noted, response will be confirmed ≥ 8 weeks off bevacizumab, via MRI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of treatment-emergent adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>Assess safety and tolerability of PVSRIPO followed by pembrolizumab via frequency and severity of treatment-emergent adverse events (TEAE) via Common Terminology Criteria for Adverse Events (CTCAE, v5.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of patients achieving stable disease (SD), CR or PR via protocol-specified response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of disease control (DDC)</measure>
    <time_frame>24 months</time_frame>
    <description>DDC ≥ 6 months for those meeting DCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival time</measure>
    <time_frame>24 months</time_frame>
    <description>If calculable, progression free survival (PFS) will be estimated based on the time from PVSRIPO infusion to death or confirmed progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival assessed by Kaplan-Meier methods</measure>
    <time_frame>24 months</time_frame>
    <description>Overall and landmark survival assessed by the proportion of patients alive at ≥ 6, ≥ 12 and at 24 months post-PVSRIPO infusion estimated by Kaplan-Meier methods.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarker identification</measure>
    <time_frame>24 months</time_frame>
    <description>Assessment of tumor tissue and blood samples for identification of genetic, cytologic, histologic and/or other markers that correlate with anti-tumor response.</description>
  </other_outcome>
  <other_outcome>
    <measure>Radiographic response/progression/PFS via iRANO</measure>
    <time_frame>24 months</time_frame>
    <description>Alternative assessment of radiographic response/progression/PFS via iRANO</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Recurrent Glioblastoma</condition>
  <condition>Supratentorial Glioblastoma</condition>
  <condition>Brain Tumor</condition>
  <arm_group>
    <arm_group_label>PVSRIPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PVSRIPO</intervention_name>
    <description>PVSRIPO (5x10^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).</description>
    <arm_group_label>PVSRIPO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>Pembrolizumab (200 mg IV) given every 3 weeks.</description>
    <arm_group_label>PVSRIPO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 18 years of age.&#xD;
&#xD;
          2. Recurrent supratentorial glioblastoma confirmed via prior histology by the site's&#xD;
             neuropathologist or designate.&#xD;
&#xD;
               -  Histologically confirmed recurrent glioblastoma within 6 weeks of PVSRIPO&#xD;
                  infusion will not require a biopsy to confirm active tumor prior to catheter&#xD;
                  placement&#xD;
&#xD;
               -  Progression of primary glioblastoma or transformation from a lower grade to a&#xD;
                  higher grade is acceptable for recurrence and as for primary glioblastoma, must&#xD;
                  be confirmed via prior histology by site pathologist&#xD;
&#xD;
          3. Enhancing lesion ≥1 cm shortest diameter to ≤ 5.5 cm longest diameter in all planes.&#xD;
&#xD;
          4. Before catheter placement based on screening MRI and at the time of catheter placement&#xD;
             via CT prior to infusion, neurosurgical investigator must confirm placement of&#xD;
             infusion catheter within or through the progressive enhancing tumor is feasible and at&#xD;
             a safe distance relative to eloquent brain function, with the tip of the catheter&#xD;
             being placed:&#xD;
&#xD;
               1. Within the enhancing portion or in the vicinity of enhancement of target lesion&#xD;
                  (ie, infiltrative disease).&#xD;
&#xD;
               2. ≥ 0.5 cm from ventricles.&#xD;
&#xD;
               3. ≥ 1 cm deep into the brain.&#xD;
&#xD;
               4. ≥ 0.5 cm from corpus callosum.&#xD;
&#xD;
          5. First or second relapse supported by MRI or CT scan; relapse is defined as progression&#xD;
             following initial/prior therapy(ies).&#xD;
&#xD;
          6. Failed previous first line therapy: maximum surgical resection and radiotherapy (RT)&#xD;
             (plus concomitant chemotherapy followed by maintenance chemotherapy if unknown or&#xD;
             methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter). Patients who begin&#xD;
             but do not complete chemotherapy/RT may still be considered for eligibility at the&#xD;
             discretion of Sponsor.&#xD;
&#xD;
          7. Karnofsky Performance Status ≥ 70 at screening and baseline.&#xD;
&#xD;
          8. Undergone prior vaccination against PV and received a boost immunization with&#xD;
             trivalent inactivated poliovirus vaccine (IPOL®) at least 1 week, but less than 6&#xD;
             weeks, prior to administration of PVSRIPO. Note: Patients who are unsure of their&#xD;
             prior vaccination status/who have not been vaccinated must provide proof of&#xD;
             vaccination and/or evidence of anti-PV immunity prior to enrollment, as applicable.&#xD;
&#xD;
          9. Ability to safely discontinue anti-coagulant therapy(ies) prior to biopsy/catheter&#xD;
             placement, as required per site/surgical guidelines.&#xD;
&#xD;
         10. Hemoglobin ≥ 9 g/dL prior to biopsy/catheter placement.&#xD;
&#xD;
         11. Platelet count ≥ 100,000/μL (unsupported); ≥ 125,000/ μL (can be supported via&#xD;
             platelet transfusion) at biopsy/catheter placement.&#xD;
&#xD;
         12. ANC ≥ 1000/μL prior to biopsy/catheter placement.&#xD;
&#xD;
         13. Creatinine ≤ 1.2 x ULN prior to biopsy/catheter placement.&#xD;
&#xD;
         14. Total bilirubin, ALT, AST, ALP ≤ 2.5 x ULN prior to biopsy/catheter placement.&#xD;
&#xD;
         15. PT and aPTT ≤ 1.2 x ULN prior to biopsy/catheter placement.&#xD;
&#xD;
         16. If undetectable ATT IgG at screen, Tdap booster vaccine ≥ 1 week prior to&#xD;
             biopsy/catheter placement.&#xD;
&#xD;
         17. Patients must be willing and able to understand and provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-&#xD;
             CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically&#xD;
             targeting T-cell co-stimulation or checkpoint pathways) ≤ 12 weeks prior to PVSRIPO&#xD;
             infusion (Note: does not apply for patients treated with pembrolizumab under this&#xD;
             protocol who are eligible for PVSRIPO retreatment). Note: patients who had previously&#xD;
             permanently discontinued any anti-PD-1 or PD-L1 therapy due to severe or&#xD;
             life-threatening immune-related AE are excluded.&#xD;
&#xD;
          2. Excluded are:&#xD;
&#xD;
               1. Neoplastic lesions in the brainstem, cerebellum, or spinal cord.&#xD;
&#xD;
               2. Radiological evidence of active/growing multifocal disease: no size increase &gt;&#xD;
                  0.5 cm in any direction of any other enhancing non-target lesions present at&#xD;
                  baseline confirmed via most recent, prior, consecutive MRIs at least 3 months&#xD;
                  apart.&#xD;
&#xD;
               3. Tumors with ≥ 1cm of contrast-enhancing tumor component crossing the midline&#xD;
                  (crossing the corpus callosum).&#xD;
&#xD;
               4. Extensive subependymal disease: multiple lesions or lesions covering &gt; 50% of&#xD;
                  subependymal space. Tumor touching subependymal space allowed.&#xD;
&#xD;
               5. Extensive leptomeningeal disease: multiple lesions or lesions covering &gt; 50% of&#xD;
                  leptomeninges. Tumor touching leptomeninges allowed.&#xD;
&#xD;
          3. Has received systemic immunosuppressive treatments other than systemic corticosteroids&#xD;
             (eg, methotrexate, chloroquine, azathioprine) within six months of PVSRIPO infusion.&#xD;
&#xD;
          4. Requires treatment with high dose systemic corticosteroids, defined as dexamethasone &gt;&#xD;
             4 mg/day or equivalent, within 2 weeks of PVSRIPO infusion.&#xD;
&#xD;
          5. Prior interstitial brachytherapy, implanted chemotherapy, stereotactic radiosurgery or&#xD;
             therapeutics delivered by local injection or CED, including PVSRIPO (except for&#xD;
             qualifying patients being retreated with PVSRIPO within this trial).&#xD;
&#xD;
          6. Pregnant and/or breast feeding female; patient/female partner of childbearing&#xD;
             potential who is unwilling to utilize protocol-defined acceptable form of&#xD;
             contraception for duration of study.&#xD;
&#xD;
          7. Impending/life-threatening cerebral herniation syndrome, per neurosurgeon/designate.&#xD;
&#xD;
          8. Severe, active co-morbidity, defined as follows:&#xD;
&#xD;
               1. Infection requiring IV treatment/unexplained febrile illness (Tmax &gt;&#xD;
                  99.5°F/37.5°C)&#xD;
&#xD;
               2. Known immunosuppressive disease/human immunodeficiency virus infection&#xD;
&#xD;
               3. Known active hepatitis B or C infection via positive viral DNA or RNA,&#xD;
                  respectively&#xD;
&#xD;
               4. Unstable or severe intercurrent medical conditions such as severe heart disease&#xD;
                  (New York Heart Association Class 3 or 4)&#xD;
&#xD;
               5. Known lung disease with forced expiratory volume in 1st second of expiration &lt;&#xD;
                  50%&#xD;
&#xD;
               6. Uncontrolled diabetes mellitus (eg, hemoglobin A1C level &gt; 7.0% with treatment)&#xD;
&#xD;
               7. History of other malignancy requiring active treatment within 2 years of&#xD;
                  biopsy/catheter placement with the exception of those with a negligible risk of&#xD;
                  metastasis or death (eg, resected cutaneous basal cell carcinoma, or other&#xD;
                  cancers with 5-year OS of &gt;90%)&#xD;
&#xD;
          9. Known albumin allergy.&#xD;
&#xD;
         10. Uncontrolled unexplained bleeding and/or hemoptysis within 4 weeks of planned PVSRIPO&#xD;
             infusion.&#xD;
&#xD;
         11. Inability to undergo brain MRI with and without contrast. History of&#xD;
             severe/anaphylactic reaction to gadolinium contrast agent is excluded. Mild allergy&#xD;
             (eg, rash) acceptable with prophylactic acetaminophen and diphenhydramine.&#xD;
&#xD;
         12. History of neurological complications due to PV infection.&#xD;
&#xD;
         13. Not recovered from toxic side effects (alopecia acceptable) and/or no current or prior&#xD;
             tumor treatments within the following timeframe relative to biopsy/catheter placement:&#xD;
&#xD;
               1. Chemotherapy or bevacizumab ≤ 4 weeks (except for nitrosourea (6 weeks) or&#xD;
                  metronomic dosed chemotherapy/targeted therapies such as daily temozolomide,&#xD;
                  etoposide or cyclophosphamide (1 week)).&#xD;
&#xD;
               2. Tumor treating fields ≤ 7 days.&#xD;
&#xD;
               3. RT of brain ≤ 12 weeks, except for progressive disease outside of the radiation&#xD;
                  field or 2 progressive scans at least 4 weeks apart or histopathologic&#xD;
                  confirmation.&#xD;
&#xD;
         14. History of agammaglobulinemia.&#xD;
&#xD;
         15. Known hypersensitivity to pembrolizumab, or any components of pembrolizumab.&#xD;
&#xD;
         16. Active autoimmune disease requiring systemic immunomodulatory treatment within the&#xD;
             past 12 months; physiologic replacement therapy (eg, thyroxine, insulin, or&#xD;
             physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency)&#xD;
             is not considered a form of systemic treatment.&#xD;
&#xD;
         17. History of other malignancy requiring active treatment within 2 years of&#xD;
             biopsy/catheter placement with the exception of those with a negligible risk of&#xD;
             metastasis or death (eg, resected cutaneous basal cell carcinoma, or other cancers&#xD;
             with 5-year OS of &gt;90%)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UConn Health</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist MD Anderson Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

